Q-omics provides the consensus-scored SPATS1 profile across patient tissues and cancer cell-line models. SPATS1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SPATS1 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, SPATS1 RNA expression shows 6,840 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, LUSC, and STAD as cancer lineages where SPATS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATS1 survival associations across molecular data types. SPATS1 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATS1 RNA expression–survival associations across cancer types. High SPATS1 expression shows unfavorable associations in HNSC, KICH, DLBC, READ and UCS, but favorable associations in PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .011). Together, the overview and detailed table identify HNSC as the clearest survival context for SPATS1 RNA expression.
This table summarizes SPATS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SPATS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATS1 shows lower tumor expression in LUSC and LUAD and higher tumor expression in BRCA. The LUSC box plot shows higher SPATS1 RNA expression in normal versus tumor tissue (log2 FC = −0.589, t-test p < 0.001).
This table shows molecular features associated with SPATS1 in patient tissues and cancer cell lines. In patient samples, SPATS1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
